P112 Significance of Low Expression of Tumor Associated Gene ki67 in Recurrence of Small Cell Lung Cancer
X. Zhang,L. Ma,Y. Hao,X. Zuo,Y. Cheng
DOI: https://doi.org/10.1016/j.jtho.2018.10.138
IF: 20.121
2018-01-01
Journal of Thoracic Oncology
Abstract:Small cell lung cancer (SCLC) has high malignancy and high metastasis rate. Ki67 as an antigen for cell proliferation, the higher the ratio, the more active the cancer cells proliferate. The aim of this study was to observe the effect of Ki67 expression on recurrence and prognosis of small cell lung cancer. From July 2013 to July 2014, 91 patients with SCLC were selected. All cases were confirmed by histopathology, and Ki67 immunohistochemical staining showed positive expression. The short-term efficacy was evaluated according to RECIST 1.1. All data were processed by SPSS 19.0 statistical software. The data were expressed by mean standard deviation (x ±s), chi-square test, Pearson linear correlation analysis, Kaplan-Meier method. and Log-rank test, P < 0.05 was statistically significant. In the study group, 47 patients (51.6%) were under 61 years, 44 (48.4%) were males, Smoking index (smoking index = annual x daily smoking) was <= 200 for 37 (40.7%) and > 400 for 35 (38.5%). 62 (68.9%) were localized tumor staging. Before chemotherapy of NSE < 11.13 ng / ml was 10 (11%) and > 25 ng/mL was 40 (44%). Ki67 expression index were 14 (15.4%) with over low expression 50-60%, 12 (13.2%) with low expression > 60-70%, 48 (52.7%) with moderate expression > 70-80%, 17 (18.7%) with high expression > 80%.In the study group, 65 patients received treatment, of which 10 (11.0%) were CR, 41 (45.1%) were PR, 13 (14.3%) were SD. Ki67 was statistically significant correlated with smoking (R=0.265, P=0.011), tumor stage (R=0.419，P<0.001), NSE (R=0.214, P=0.042) and optimal efficacy (R=0.244, P=0.02). The median PFS of low expression, low expression, moderate expression and high expression of Ki67 were 408, 538, 228 and 343 days, respectively (P = 0.042). In particular, when the expression of Ki67 was 70% as the dividing line, = < 70% as the low expression, and > 70% as the high expression, the PFS was 434 days and 261 days, respectively (P=0. 027). However, there was no significant correlation between Ki67 and OS (2-year survival rate) (P > 0. 05). The lower expression of Ki67 in SCLC is better for drug efficacy, and longer PFS.Ki67 may be one of the predictors of SCLC recurrence. In particular, 70% Ki67 expression index is an important critical index for the progression of small cell lung cancer. In particular, 70% of Ki67 expression index is an important critical index for the progression of SCLC.